Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

    -- Phase II SP 667 - 200, 400, 600 mg/day* Vimpat(R)
    -- Phase III SP 754 - 400, 600 mg/day* Vimpat(R)
    -- Phase III SP 755 - 200, 400 mg/day Vimpat(R)

* The 600 mg/day dose of Vimpat(R) is not approved by the FDA. In clinical trials, the 600 mg daily dose was not more effective than the 400 mg daily dose, and was associated with a substantially higher rate of adverse reactions. Vimpat(R) dosing should start at 50 mg twice daily and maybe increased to a daily dose of 200 to 400 mg per day (recommended therapeutic dosing) administered in two divided doses.

The primary endpoints of the studies were the median percent reduction in seizure frequency per 28 days from the baseline to the maintenance period and the 50 percent responder rate, defined as the proportion of patients experiencing a 50 percent or greater reduction in partial seizure frequency per 28 days from the baseline to the maintenance period.

The studies involved a total of more than 1,300 patients, with 944 randomized to receive Vimpat(R) at one of the three doses (200 mg/day, n=270; 400 mg/day, n=471; 600 mg/day, n=203) and 364 randomized to the placebo group. Patients in the treatment groups received Vimpat(R) at 100 mg/day (50 mg twice daily) during the initial week of treatment, followed by weekly titration in 100 mg/day increments to the assigned targeted dose.

This patient group had been living with epilepsy for an average of almost 24 years. Overall, 77.4 percent of patients had tried four or more AEDs in their lifetime and 45.2 percent had tried seven or more. Most patients (84.4 percent) were taking two or three concomitant AEDs at the time of study entry, mainly carbamazepine (35.2 percent), lamotrigine (31.2 percent), levetiracetam (29.0 percent), valproate (23.6 percent), and topiramate (22.3 percent). At baseline, patients reported more than two to three times the number of seizures per 2
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 a2z Inc. announces ... Mobile App, AACC Pathfinder, in its 2014 Annual ... annual meeting is planned for July 29-31, 2014 in ... to be to connect with global leaders in clinical ... and other areas of breaking science in laboratory medicine. ...
(Date:7/22/2014)... Web) July 21, 2014 (PRWEB) July 23, 2014 ... Biomaterials, at Rutgers University. , The goal ... ideas across the full spectrum of scientists working ... research and development topics that represent the most ... been programmed to:,     Provide faculty ...
(Date:7/22/2014)... and Technology (NIST) and California Institute of Technology ... atomic clock that is based on a chip-scale ... clock, featured on the cover of the inaugural ... is the first demonstration of all-optical control of ... frequencies to lower microwave frequencies. (Optical frequencies are ...
(Date:7/22/2014)... , July 22, 2014   BioTE ... therapy using natural, bio-identical hormone pellets, today announced ... MD to the company.   Dr. Rouzier is joining ... physician.      Dr. Rouzier was residency ... UCLA and is a board certified emergency physician ...
Breaking Biology Technology:AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2'Comb on a chip' powers new NIST/Caltech atomic clock design 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3
...  Signaling a further commitment to expand its business model in ... of the largest imaging and cardiac safety core labs ... the opening of an office in Tokyo, Japan under the ... "We are pleased to announce the creation of our new ...
... Wis., Jan. 16, 2012 PuraMed BioScience, Inc. (OTCBB:PMBS) ... Baacke, CPA, to the position of Chief Financial Officer. ... the Corporate Controller for PuraMed BioScience, Inc. gaining extensive ... came to PuraMed after holding a supervisory position at ...
... Regenesis Biomedical, Inc., a medical technology company that ... Scott Brooks has joined the company in the ... is responsible for helping scale the organization,s capabilities ... (Logo: http://photos.prnewswire.com/prnh/20120109/LA31405LOGO ) ...
Cached Biology Technology:CoreLab Partners Opens Office in Tokyo, Japan 2PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO 2Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer 2
(Date:7/23/2014)... the world by 2050, according to one of the ... (IPCC), may be advantageous to the physiology and the ... forage plants such as Stylosanthes capitata Vogel , ... such as Brazil., The conclusion is from a study ... at the Ribeiro Preto Faculty of Philosophy, Sciences and ...
(Date:7/23/2014)... MA -- What do mollusks, starfish, and corals ... habitat, they are all calcifiersorganisms that use calcium ... and shells for stability and protection. , The ... published by the Marine Biological Laboratory, addresses the ... changes worldwide. , As atmospheric carbon dioxide rises, ...
(Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
Breaking Biology News(10 mins):An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Calcification in changing oceans explored in special issue of The Biological Bulletin 2MedNet Appoints Clareece West As Chief Operating Officer 2
... Nanoparticles will soon be used as tiny shuttles to ... a more targeted way than was possible in the ... the nanoparticles in medicine, concerns have arisen about their ... nanoparticles and their toxicity rely on the ability of ...
... Mass. April 28, 2011 A project to use ... $100,000 grant from The Bill & Melinda Gates Foundation today. ... of the Harvard School of Engineering and Applied Sciences (SEAS) ... aim is to develop a Microbial Fuel Cell-based charger that ...
... One of the most critical tasks that a dividing ... set of genetic information to each new daughter cell. Now, ... issue of the journal Cell , provides fascinating new ... segregation of human chromosomes during cell division. During ...
Cached Biology News: Inverting a standard experiment sometimes produces different results 2 Inverting a standard experiment sometimes produces different results 3Harvard's engineering school receives $100,000 Grand Challenges Explorations grant 2Harvard's engineering school receives $100,000 Grand Challenges Explorations grant 3New insight into chromosome segregation: Centromere-independent kinetochore assembly 2
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
... Human serum is obtained from normal human ... by a test for Human Immunodeficiency Virus ... Virus (Anti-HIV 1/2), Hepatitis C Virus (HCV), ... (HbsAg) and Non-reactive by a screening test ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
Values of steady state parameters for enzyme activities are determined....
Biology Products: